MLLT3 and leukemia: Although we did not observe significant changes in the frequencies of YFP+ leukemia cells in the peripheral blood at 5 weeks post-transplantation (Figure 1C–1D), the recipients of MLL-AF9-transduced ChREBP-null cells had a significantly reduced survival upon secondary transplantation (Figure 1E).